Storm Therapeutics, is a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, opening up novel therapeutic targets in cancer treatment. Storm Therapeutics is based in Cambridge, UK.
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models
STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors
TORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe as Senior Vice President of Therapeutics and the promotion of Beth Thomas to Vice President of Medicinal Chemistry.
2022/12/14STORM Therapeutics announces closing of USD $30M Series B financing
Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)
STORM Therapeutics today announces that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies
STORM Therapeutics today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony
STORM today announced the appointment of Nobel Prize Winner professor Thomas Cech as a Scientific Advisor
Taiho Ventures First Investment in Europe
STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of both Professor Mark Dawson and Dr Paul Leeson to the Scientific Advisory Board.
New Drug Target Discovered For Acute Myeloid Leukaemia
STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML)
STORM Therapeutics, the drug discovery company focused on the
discovery of small molecule therapies modulating RNA epigenetics, today announced the
appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution
of its management and advisory networks as it fulfils its ambition to become the leading therapeutics
company in RNA epigenetic modulation.
Storm is tapping the nascent field of RNA epigenetics for cancer
STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery
CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.
Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics
28 June 2016
Cambridge, UK - Storm Therapeutics, a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, M Ventures and Pfizer Venture Investments.
Storm Therapeutics is based upon the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.
